Claims
- 1. A compound of the general formula and pharmaceutically acceptable salts thereof: ##STR18## wherein: R.sup.1 =HO or HOOC(CH.sub.2).sub.x CHR.sup.2 NH--;
- R.sup.2 =H, lower alkyl, benzyl or --CH.sub.2 OH;
- x=0 or 1;
- A=--(CH.sub.2).sub.n --or ##STR19## n=1 to 5; and R=lower alkyl;
- Y=H, Cl or OCH.sub.3;
- Z=H or Cl;
- m=0 or 1;
- with the proviso that where R.sup.1 =OH, Y is H or Cl and m is 1, then n is 4 or 5.
- 2. The compound of claim 1, wherein R.sup.1 is OH, A is --(CH.sub.2).sub.4 --, R is C.sub.2 H.sub.5, Y and Z are Cl and m is 1.
- 3. The compound of claim 1, wherein R.sup.1 is OH, A is --(CH.sub.2).sub.5 --, R is C.sub.2 H.sub.5, Y and Z are Cl and m is 1.
- 4. The compound of claim 1, wherein R.sup.1 is OH, A is ##STR20## R is C.sub.2 H.sub.5, Y and Z are Cl and m is 1.
- 5. The compound of claim 1, wherein A is ##STR21## R is CH.sub.2 CH.sub.2 CH.sub.3, Y and Z are Cl and m is 1.
- 6. The compound of claim 1, wherein R.sup.1 is HOOCCH.sub.2 NH, A is --(CH.sub.2).sub.3 --, R is C.sub.2 H.sub.5, Y and Z are Cl and m is 1.
- 7. The compound of claim 1, wherein R.sup.1 is S(+)- HOOCCH(CH.sub.3)NH--, A is --(CH.sub.2).sub.3 --, R is C.sub.2 H.sub.5, Y and Z are Cl and m is 1.
- 8. The compound of claim 1, wherein R.sup.1 is S(+)- HOOCCH [CH.sub.2 CH(CH.sub.3).sub.2 ]NH, A is --(CH.sub.2).sub.3 --, R is C.sub.2 H.sub.5, Y and Z are Cl and m is 1.
- 9. The compound of claim 1, wherein R.sup.1 is S(+)- HOOCCH(CH.sub.2 OH)NH--, A is --(CH.sub.2).sub.3 --, R is C.sub.2 H.sub.5, Y and Z are Cl and m is 1.
- 10. The compound of claim 1, wherein R.sup.1 is S(-)- HOOCCH(CH.sub.2 C.sub.6 H.sub.5)NH--, A is --(CH.sub.2).sub.3 --, R is C.sub.2 H.sub.5, Y and Z are Cl and m is 1.
- 11. The compound of claim 1, wherein R.sup.1 is HOOCCH.sub.2 NH--, A is --(CH.sub.2).sub.3 --, R is CH.sub.2 CH.sub.2 CH.sub.3, Y and Z are Cl and m is 1.
- 12. The compound of claim 1, wherein R.sup.1 is HOOCCH.sub.2 NH--, A is ##STR22## R is C.sub.2 H.sub.5, Y and Z are Cl and m is 1 .
- 13. The compound of claim 1, wherein R.sup.1 is HOOCCH.sub.2 NH, A is --(CH.sub.2).sub.2 --, R is C.sub.2 H.sub.5, Y and Z are Cl and m is 1.
- 14. The compound of claim 1, wherein R.sup.1 is HOOCCH.sub.2 NH--, A is --(CH.sub.2).sub.4 --, R is C.sub.2 H.sub.5, Y and Z are Cl and m is 1.
- 15. The compound of claim 1, wherein R.sup.1 is HOOCCH.sub.2 NH--, A is --(CH.sub.2).sub.5 --, R is C.sub.2 H.sub.5, Y and Z are Cl and m is 1.
- 16. The compound of claim 1, wherein R.sup.1 is HOOCCH.sub.2 CH.sub.2 NH, A is ##STR23## R is C.sub.2 H.sub.5, Y and Z are Cl and m is 1.
- 17. The compound of claim 1, wherein R.sup.1 is OH, Y is OCH.sub.3, Z is H, R is CH.sub.3, A is CH.sub.2 and m is 1.
- 18. An anti-sickling pharmaceutical composition comprising a pharmaceutical carrier and an anti-sickling agent of the general formula and pharmaceutically acceptable salts thereof: ##STR24## wherein: R.sup.1 =HO or HOOC(CH.sub.2).sub.x CHR.sup.2 NH--;
- R.sup.2 =H, lower alkyl, benzyl or --CH.sub.2 OH;
- x=0 or 1;
- A=--(CH.sub.2).sub.n -- or ##STR25## n=1 to 5; and Y=H, Cl or OCH.sub.3 ;
- Z=H or Cl;
- m=0 or 1; with the proviso that where R.sup.1 =OH, Y is H or Cl and m=1, then n is 4 to 5;
- R=lower alkyl.
- 19. A method of treating a person for sickle cell anemia comprising administering to the person a therapeutically effective dosage of a compound of the general formula and pharmaceutically acceptable salts thereof: wherein: ##STR26## wherein: R.sup.1 =HO or HOOC(CH.sub.2).sub.X CHR.sup.2 NH--;
- R.sup.2 =H, lower alkyl, benzyl or --CH.sub.2 OH;
- x=0 or 1;
- A=--(CH.sub.2).sub.n --or ##STR27## n=1 to 5; and Y=H, Cl or OCH.sub.3
- Z=H or Cl
- m=0 or 1
- R=lower alkyl.
- 20. The compound of claim 1, wherein R.sup.1 is OH, Y is H, Z is Cl, R is C.sub.2 H.sub.5 and m is 0.
- 21. The antisickling compositon of claim 18 wherein the antisickling agent is the compound wherein R.sup.1 is OH, Y and Z are H, A is CH.sub.2, R is CH.sub.3 and m is 1.
- 22. The method of treating a person for sickle cell anemia comprising administering to the person a therapeutically effective dosage of the compound of claim 19 wherein R.sup.1 is OH, Y and Z are H, A is CH.sub.2, R is CH.sub.3, and m is 1.
- 23. The method of treating a person for sickle cell anemia comprising administering to the person a therapeutically effective dosage of the compound of claim 19 wherein R.sup.1 is OH, Y and Z are Cl, A is (CH.sub.2).sub.3, R is C.sub.2 H.sub.5 and m is 1.
CROSS REFERENCE TO RELATED APPLICATION
This application is a continuation of applicant's co-pending application Ser. No. 848,079, filed Apr 4, 1986, now abandoned.
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
3409661 |
Schultz et al. |
Nov 1968 |
|
3445503 |
Schultz et al. |
May 1969 |
|
3860639 |
Schultz |
Jan 1975 |
|
Continuations (1)
|
Number |
Date |
Country |
Parent |
848079 |
Apr 1986 |
|